July 21, 2025
— Jeff Ward, Lehigh Valley News Briefs
OraSure Technologies, which makes diagnostic tools and fritters away investors’ wealth, will report second-quarter financial results on Aug. 5.
The Bethlehem-based company (NASDAQ:OSUR) traded at $3.25 at 4 p.m. today. In the last 52 weeks, it has traded as high as $4.92 and as low as $2.36. The stock has been dropping since the COVID-19 pandemic, with a little surge up now and then.
Recently, Reuters reported that an investor bid for the company, valuing it at perhaps $3.50 to $4 per share. The company rejected the bid, Reuters reported, citing anonymous people.
While the company needs something, a bid that values it at not much above its cash per share will not satisfy institutional investors.
As of March 31, OraSure had $248 million in cash and equivalents. It has since then embarked upon in my humble opinion an ill-conceived $40 million share buyback.
Trading cash, which is good, for OraSure stock, which has been a dog for years, doesn’t strike me as wise, and after a brief rise in the stock when the repurchase was announced, shares fell again.
That’s what OraSure stock does over time: it falls. Nothing the company has done internally has helped, and it last reached around $18 or so when the federal government was giving OraSure money for COVID-19 tests and a new factory in Bethlehem Township during the pandemic.
At today’s closing price, the company has a market capitalization of $243.1 million.
OraSure was founded in the 1980s as SolarCare, a maker of sunscreen towelettes. Now it makes the InteliSwab COVID-19 test, the OraQuick HIV test, and specimen-collection devices.
Chief Executive Carrie Eglinton Manner says she is leading the company toward efficiency and to be a leader in making medical tests that people can use at home.
We will see. Maybe if a reasonable buyout offer were made, long-term investors would be ready to bail out. So far, I have not seen any OraSure comment on the buyout bid.
I would like to see the company stay local and independent, but after more than three years under Eglinton Manner’s leadership, nothing big has happened as far as the stock price.
The company usually reports earnings shortly after 4 p.m. on the announced date. The company will hold a conference call with the investment community at 5 p.m. Aug. 5.
If nothing about the buyout comes up before then, perhaps some light will be shed on it during the call with Wall Street analysts.
— Disclosure: I do not recommend day-trading, but sometimes I buy some OSUR stock and sell it after it’s gone up enough for me to buy a pizza.
Here’s a link to the release and below is a cut-and-paste version:
OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th
July 21, 2025 at 4:05 PM EDT
BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025.
A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has ended and will be available for approximately one year.
For participants interested in asking questions during the conference call, please follow the link below to pre-register. After registering, you will be provided with access details via email.
https://register-conf.media-server.com/register/BIdfa47088da4a422f967ac3a63ee20f09
About OraSure Technologies, Inc.
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com
Lehigh Valley News Briefs 